Peptide Cegrilentide (Cagrilintide)

Review of the experimental peptide Cegrilentide, a synthetic analog of the hormone amylin as an appetite suppressant for fat burning through two independent pathways.

2. Specific tips and tricks

  • Reception protocol: One injection per week.
  • Immune attack!Dosage scheme (‘ladder’): Starting from 0.25-0.3 mg, increasing the dose every 4 weeks: 0.5 mg → 1 mg → 1.7 mg → 2.4 mg (therapeutic dose). If necessary, increase to 4.5 mg.

3. Scientific justifications and claimed effects

Mechanism of action: It is an agonist of amylin receptors (not GLP-1). Suppresses appetite in two ways:

  1. Homeostatic: Reduces hunger (like GLP-1).
  2. Hedonistic: It blocks the enjoyment of food by affecting dopamine, opioid, and cannabinoid receptors in the brain.

4. Critical comments

Drug status: Kegrilentayd is an experimental drug. it has not been approved by any regulatory agency in the world (FDA, EMA) for clinical use. All data are the results of intermediate clinical trials. Its safety during long-term use has not been studied.

Side effects: Usually only nausea and injection site reactions are mentioned. However, amylin and GLP-1 agonists have serious potential risks: pancreatitis, cholecystitis, diabetic retinopathy, acute renal failure, suicidal thoughts.

Dangerous tips:

The advice ‘do not change your diet’ is extremely harmful. The goal of therapy is to develop healthy eating habits, and not just suppress appetite with chemicals.

Obesity is a complex multi-factorial disease that requires a comprehensive approach (diet, psychotherapy, physical activity, medical treatment under the supervision of a doctor).

5. Summary and conclusions

  • Dry matter: Kegrilentide is a promising investigational drug that has shown high efficacy in clinical trials in combination with GLP-1 agonists for the treatment of obesity.